Dimitri Renard1, Giovanni Castelnovo1, Laurent Collombier2, Eric Thouvenot1,3, Vincent Boudousq2,4. 1. a Department of Neurology , Nîmes University Hospital , Nîmes , France. 2. b Department of Nuclear Medicine , Nîmes University Hospital , Nîmes , France. 3. c Institut de Génomique Fonctionnelle, UMR5203, Université Montpellier , Montpellier , France. 4. d IRCM, Inserm, University of Montpellier, ICM , Montpellier , France.
Abstract
OBJECTIVE: To assess the relationship between clinical pattern and cerebral glucose metabolism on [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in Creutzfeldt-Jakob disease (CJD). METHODS: Predefined clinical signs (ataxia, visual, pyramidal, myoclonus, limb apraxia, limb dystonia, sensory, parkinsonism, and corticobasal syndrome [CBS]) and FDG-PET data were assessed in consecutive CJD patients. Two types of statistical parametric mapping (SPM) analyses, using stringent level of significance p < 0.001 and extent threshold of 100 voxels, were performed: one comparing CJD patients presenting specific sign against CJD patients without this specific sign (inter-CJD analysis), and one comparing CJD patients with specific sign against 18 healthy controls (CJD-control analysis). RESULTS: Fifteen CJD patients (11 probable and two histologically proven sporadic and two genetic CJD) were analyzed. CJD-control analysis of the entire CJD group showed lateralized frontal and parietal hypometabolism. When analyzing clinical CJD subgroups, inter-CJD analyses showed hypometabolism in more restricted areas than on CJD-control analyses. For CJD patients presenting with ataxia, visual signs and CBS (and CBS-associated signs), additional hypometabolic areas probably related to the specific signs were identified: pons and middle cerebellar peduncles in patients with ataxia; occipital cortex in patients with visual signs; and prerolandic and lateral parietal cortex in patients with CBS. For pyramidal signs, sensory loss, and parkinsonism, no abnormalities in brain areas typically involved in these signs were observed. CONCLUSION: In addition to lateralized frontal and parietal hypometabolism previously reported in CJD and observed here, hypometabolism in brain areas related to some specific signs (i.e. ataxia, visual signs, and CBS) is also seen.
OBJECTIVE: To assess the relationship between clinical pattern and cerebral glucose metabolism on [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in Creutzfeldt-Jakob disease (CJD). METHODS: Predefined clinical signs (ataxia, visual, pyramidal, myoclonus, limb apraxia, limb dystonia, sensory, parkinsonism, and corticobasal syndrome [CBS]) and FDG-PET data were assessed in consecutive CJDpatients. Two types of statistical parametric mapping (SPM) analyses, using stringent level of significance p < 0.001 and extent threshold of 100 voxels, were performed: one comparing CJDpatients presenting specific sign against CJDpatients without this specific sign (inter-CJD analysis), and one comparing CJDpatients with specific sign against 18 healthy controls (CJD-control analysis). RESULTS: Fifteen CJDpatients (11 probable and two histologically proven sporadic and two genetic CJD) were analyzed. CJD-control analysis of the entire CJD group showed lateralized frontal and parietal hypometabolism. When analyzing clinical CJD subgroups, inter-CJD analyses showed hypometabolism in more restricted areas than on CJD-control analyses. For CJDpatients presenting with ataxia, visual signs and CBS (and CBS-associated signs), additional hypometabolic areas probably related to the specific signs were identified: pons and middle cerebellar peduncles in patients with ataxia; occipital cortex in patients with visual signs; and prerolandic and lateral parietal cortex in patients with CBS. For pyramidal signs, sensory loss, and parkinsonism, no abnormalities in brain areas typically involved in these signs were observed. CONCLUSION: In addition to lateralized frontal and parietal hypometabolism previously reported in CJD and observed here, hypometabolism in brain areas related to some specific signs (i.e. ataxia, visual signs, and CBS) is also seen.
Authors: Will Lee; Marion Simpson; Helen Ling; Catriona McLean; Steven Collins; David R Williams Journal: Parkinsonism Relat Disord Date: 2012-09-01 Impact factor: 4.891
Authors: I Zerr; K Kallenberg; D M Summers; C Romero; A Taratuto; U Heinemann; M Breithaupt; D Varges; B Meissner; A Ladogana; M Schuur; S Haik; S J Collins; Gerard H Jansen; G B Stokin; J Pimentel; E Hewer; D Collie; P Smith; H Roberts; J P Brandel; C van Duijn; M Pocchiari; C Begue; P Cras; R G Will; P Sanchez-Juan Journal: Brain Date: 2009-09-22 Impact factor: 13.501
Authors: Nick Corriveau-Lecavalier; Wentao Li; Vijay K Ramanan; Daniel A Drubach; Gregory S Day; David T Jones Journal: J Neurol Date: 2022-03-01 Impact factor: 6.682
Authors: Peter Hermann; Brian Appleby; Jean-Philippe Brandel; Byron Caughey; Steven Collins; Michael D Geschwind; Alison Green; Stephane Haïk; Gabor G Kovacs; Anna Ladogana; Franc Llorens; Simon Mead; Noriyuki Nishida; Suvankar Pal; Piero Parchi; Maurizio Pocchiari; Katsuya Satoh; Gianluigi Zanusso; Inga Zerr Journal: Lancet Neurol Date: 2021-03 Impact factor: 44.182
Authors: Stephen C Cunnane; Mark J Millan; Eugenia Trushina; Cecilie Morland; Alessandro Prigione; Gemma Casadesus; Zane B Andrews; M Flint Beal; Linda H Bergersen; Roberta D Brinton; Suzanne de la Monte; Anne Eckert; Jenni Harvey; Ross Jeggo; Jack H Jhamandas; Oliver Kann; Clothide Mannoury la Cour; William F Martin; Gilles Mithieux; Paula I Moreira; Michael P Murphy; Klaus-Armin Nave; Tal Nuriel; Stéphane H R Oliet; Frédéric Saudou; Mark P Mattson; Russell H Swerdlow Journal: Nat Rev Drug Discov Date: 2020-07-24 Impact factor: 84.694
Authors: Stefan M Golaszewski; Bettina Wutzl; Axel F Unterrainer; Cristina Florea; Kerstin Schwenker; Vanessa N Frey; Martin Kronbichler; Frank Rattay; Raffaele Nardone; Larissa Hauer; Johann Sellner; Eugen Trinka Journal: Diagnostics (Basel) Date: 2020-05-15
Authors: Julius Obergassel; Lisa Lohmann; Sven G Meuth; Heinz Wiendl; Oliver Grauer; Christopher Nelke Journal: Prion Date: 2020-12 Impact factor: 3.931
Authors: Lucas M Ascari; Stephanie C Rocha; Priscila B Gonçalves; Tuane C R G Vieira; Yraima Cordeiro Journal: Front Bioeng Biotechnol Date: 2020-10-20